Deutsche Bank’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.17M Buy
353,552
+378
+0.1% +$5.6K ﹤0.01% 1353
2026
Q1
$5.12M Buy
353,174
+271,884
+334% +$3.16M ﹤0.01% 1286
2025
Q4
$781K Hold
81,290
﹤0.01% 2329
2025
Q3
$764K Hold
81,290
﹤0.01% 2318
2025
Q2
$860K Sell
81,290
-3,969
-5% -$50.1K ﹤0.01% 2176
2025
Q1
$1.28M Buy
85,259
+10,760
+14% +$179K ﹤0.01% 2020
2024
Q4
$1.23M Sell
74,499
-11,805
-14% -$233K ﹤0.01% 2134
2024
Q3
$2.13M Buy
86,304
+3,686
+4% +$95.6K ﹤0.01% 1699
2024
Q2
$2.09M Sell
82,618
-208
-0.3% -$5.39K ﹤0.01% 1616
2024
Q1
$2.1M Buy
82,826
+770
+0.9% +$18.6K ﹤0.01% 1637
2023
Q4
$1.86M Buy
82,056
+74,139
+936% +$1.53M ﹤0.01% 1716
2023
Q3
$147K Sell
7,917
-73,025
-90% -$1.51M ﹤0.01% 2968
2023
Q2
$2.1M Buy
80,942
+45,148
+126% +$1.21M ﹤0.01% 1594
2023
Q1
$1.03M Buy
35,794
+2,927
+9% +$87.1K ﹤0.01% 2083
2022
Q4
$973K Buy
32,867
+126
+0.4% +$3.58K ﹤0.01% 2072
2022
Q3
$780K Sell
32,741
-853
-3% -$19.6K ﹤0.01% 2119
2022
Q2
$750K Sell
33,594
-960
-3% -$21.4K ﹤0.01% 2351
2022
Q1
$868K Sell
34,554
-940
-3% -$28.7K ﹤0.01% 2440
2021
Q4
$1.27M Sell
35,494
-133
-0.4% -$5.32K ﹤0.01% 2287
2021
Q3
$1.52M Buy
35,627
+237
+0.7% +$9.76K ﹤0.01% 2324
2021
Q2
$1.53M Buy
35,390
+18,831
+114% +$802K ﹤0.01% 2465
2021
Q1
$675K Buy
16,559
+6,662
+67% +$253K ﹤0.01% 2902
2020
Q4
$448K Sell
9,897
-3,165
-24% -$120K ﹤0.01% 2981
2020
Q3
$462K Sell
13,062
-85,632
-87% -$3.09M ﹤0.01% 2679
2020
Q2
$3.72M Sell
98,694
-5,431
-5% -$179K ﹤0.01% 1460
2020
Q1
$3.01M Sell
104,125
-17,875
-15% -$723K ﹤0.01% 1494
2019
Q4
$6.32M Buy
122,000
+111,804
+1,097% +$6.49M ﹤0.01% 1316
2019
Q3
$558K Sell
10,196
-29,683
-74% -$1.52M ﹤0.01% 2624
2019
Q2
$1.62M Sell
39,879
-75,687
-65% -$2.76M ﹤0.01% 2539
2019
Q1
$3.49M Buy
115,566
+13,517
+13% +$463K ﹤0.01% 2104
2018
Q4
$3.43M Sell
102,049
-192,056
-65% -$6.93M ﹤0.01% 2046
2018
Q3
$12.4M Sell
294,105
-77,082
-21% -$3.05M 0.01% 1470
2018
Q2
$11.9M Buy
371,187
+235,803
+174% +$9.71M 0.01% 1603
2018
Q1
$6.73M Buy
135,384
+44,800
+49% +$2.53M ﹤0.01% 1961
2017
Q4
$4.88M Buy
90,584
+21,906
+32% +$1.21M ﹤0.01% 2049
2017
Q3
$3.98M Buy
68,678
+5,202
+8% +$272K ﹤0.01% 2059
2017
Q2
$3.13M Sell
63,476
-12,959
-17% -$597K ﹤0.01% 2259
2017
Q1
$3.32M Buy
76,435
+18,398
+32% +$878K ﹤0.01% 1925
2016
Q4
$2.84M Sell
58,037
-30,466
-34% -$1.41M ﹤0.01% 2031
2016
Q3
$4.23M Sell
88,503
-29,292
-25% -$1.45M ﹤0.01% 1851
2016
Q2
$6.32M Buy
117,795
+35,337
+43% +$1.66M ﹤0.01% 1588
2016
Q1
$3.69M Buy
82,458
+40,537
+97% +$1.64M ﹤0.01% 1957
2015
Q4
$1.6M Sell
41,921
-5,145
-11% -$197K ﹤0.01% 2597
2015
Q3
$1.5M Sell
47,066
-9,059
-16% -$316K ﹤0.01% 2676
2015
Q2
$1.85M Buy
56,125
+16,184
+41% +$577K ﹤0.01% 2509
2015
Q1
$1.64M Sell
39,941
-16,726
-30% -$676K ﹤0.01% 2576
2014
Q4
$2.31M Buy
56,667
+24,626
+77% +$963K ﹤0.01% 2562
2014
Q3
$1.17M Sell
32,041
-38,775
-55% -$1.68M ﹤0.01% 2910
2014
Q2
$3.28M Sell
70,816
-16,510
-19% -$734K ﹤0.01% 2130
2014
Q1
$3.59M Buy
87,326
+71,422
+449% +$2.65M ﹤0.01% 2044
2013
Q4
$606K Buy
15,904
+1,598
+11% +$49.3K ﹤0.01% 2967
2013
Q3
$341K Buy
14,306
+4,947
+53% +$111K ﹤0.01% 3772
2013
Q2
$158K Buy
+9,359
New +$135K ﹤0.01% 3969

Other funds holding ANIK

Deutsche Bank's ANIK Position: Q2 2026 in Review

Deutsche Bank increased its Anika Therapeutics (ANIK) stake by 0.11% in Q2 2026, buying an estimated $5.6K and bringing the position to 353,552 shares worth $5.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Deutsche Bank first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.4M in Q3 2018. 43 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Deutsche Bank held 353,552 shares of Anika Therapeutics worth $5.17M as of Q2 2026.
  • Deutsche Bank bought 378 Anika Therapeutics shares in Q2 2026, an estimated $5.6K.
  • Anika Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1353 holding.
  • Deutsche Bank first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Anika Therapeutics position peaked at $12.4M in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.